Learn how the inhibition constant and 5-HT2A binding explain LSD effects—and why potent atypical antipsychotics may rapidly end a bad trip.
|Poll|June 3, 2022
The Role of Psychedelics in Psychiatry: Helpful or Hoax?
Author(s)Psychiatric Times Editors
What are your thoughts on psychedelics?
Advertisement
Some say we are undergoing a
Do you think psychedelics can play a productive role in addressing psychiatric disorders?
Would you recommend psychedelics to your patients?
Have you referred your patients for psychedelic treatment/have any one of your patients received psychedelic-assisted therapy?
We want to know more about your thoughts and experiences with psychedelics and clinical practice! Write to us at
Advertisement
Related to this article
FDA hearing spotlights debates over psychedelic therapy: who administers, how to prove efficacy, and how to track safety as approvals near.
Single-dose DT120 ODT delivers rapid, sustained anxiety relief in phase 3 GAD trial, supporting FDA breakthrough path and NDA plans.
Health Canada has authorized a 200-participant phase 2 trial testing a single psilocybin dose for major depressive disorder, with dosing set to begin in 2027.
Psychedelic psilocybin therapy shows year-long relief in treatment-resistant depression, with strong response rates and stable safety.
FDA boosts DT120 lysergide ODT after phase 3 shows lasting depression relief; psychedelic tablet also advances for anxiety and other brain disorders.
New trial shows edible THC worsens lane control and reaction time at low blood levels, raising doubts about current legal impairment limits.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Insights on the New Adult ADHD Guidelines: A Conversation With the President of APSARD
2
FDA Hearing on Psychedelic Medicine Reveals a Field Divided on the Road to Approval
3
Centanafadine For Comorbid ADHD and Anxiety: Talking New Data With John Kraus, MD, PhD
4
New Adult ADHD Guidelines: What Resources Are Coming Soon
5